# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Brainstorm Cell (NASDAQ:BCLI) reported quarterly losses of $(0.04) per share which met the analyst consensus estimate. This is ...
CMC FDA Questions Resolved, PIIIb Rollout Begins, $4M Raised, Commercialization Team In Place; Signed CRO And Lined Up Commerci...
Maxim Group analyst Jason McCarthy upgrades Brainstorm Cell (NASDAQ:BCLI) from Hold to Buy and announces $2 price target.
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative dise...
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative dise...